激素替代療法

激素替代療法（英語：hormone replacement therapy , HRT；menopausal hormone therapy (MHT)、postmenopausal hormone therapy (PHT, PMHT)）或荷爾蒙補充療法。是一種荷爾蒙療法，用於治療女性更年期相關的症狀。^{[註 1]}^[1]^[2]這些症狀可能包括潮熱，陰道萎縮和乾燥，以及骨質流失等，並且是由更年期期間性激素水平降低引起的。^[3]^[4]激素替代療法用於更年期症狀的主要激素藥物是雌激素和孕激素。^[5]對於擁有完整子宮的女性，孕激素通常與雌激素聯合使用，因為無對抗的雌激素治療與子宮內膜增生和癌症有關，而孕激素可預防這些風險。^[5]^[6]^[7]像睪酮這樣的雄激素有時也用於激素替代療法。^[8]激素替代療法藥物有多種形式，可通過各種不同的給藥途徑使用。^[5]

注釋

[註 1]
性別肯定激素治療(GAHT)也屬於HRT，一般而言，HRT是對於順性別女性的激素補充療法，為了區分，本條目不包含GAHT的內容介紹。

參考資料

[1]
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. November 2015, 100 (11): 3975–4011. PMID 26444994. doi:10.1210/jc.2015-2236.
[2]
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. July 2010, 95 (7 Suppl 1): s1–s66. PMID 20566620. doi:10.1210/jc.2009-2509.
[3]
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. November 2015, 100 (11): 3975–4011. PMID 26444994. doi:10.1210/jc.2015-2236.
[4]
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. July 2010, 95 (7 Suppl 1): s1–s66. PMID 20566620. doi:10.1210/jc.2009-2509.
[5]
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2018-08-17]. PMID 16112947. doi:10.1080/13697130500148875. （原始內容存檔 (PDF)於2019-03-27）.
[6]
Shuster, Lynne T.; Rhodes, Deborah J.; Gostout, Bobbie S.; Grossardt, Brandon R.; Rocca, Walter A. Premature menopause or early menopause: Long-term health consequences. Maturitas. 2010, 65 (2): 161–166. ISSN 0378-5122. PMC 2815011 . PMID 19733988. doi:10.1016/j.maturitas.2009.08.003.
[7]
Eden, K.J., & Wylie, K.R. (2009). Quality of sexual life and menopause. Women’s Health, 5 (4), 385-396. doi:10.2217/whe.09.24
[8]
Ziaei, S., Moghasemi, M., & Faghihzadeh, S. (2010). Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climateric, 13, 147-156. doi:10.1016/j.maturitas.2006.04.014

參見

6-甲氫化潑尼松（英語：Methylprednisolone） (甲強龍)
性別肯定激素治療（與HRT相類似的療法）

外部連結

Menopause treatment （頁面存檔備份，存於網際網路檔案館）, Hormone Health Network, The Endocrine Society
Sexual Health and Menopause Online （頁面存檔備份，存於網際網路檔案館）, The North American Menopause Society
Menopause （頁面存檔備份，存於網際網路檔案館）, US Food and Drug Administration

[1] [註 1]
性別肯定激素治療(GAHT)也屬於HRT，一般而言，HRT是對於順性別女性的激素補充療法，為了區分，本條目不包含GAHT的內容介紹。

[pmid264449942-2] [1]
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. November 2015, 100 (11): 3975–4011. PMID 26444994. doi:10.1210/jc.2015-2236.

[pmid205666202-3] [2]
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. July 2010, 95 (7 Suppl 1): s1–s66. PMID 20566620. doi:10.1210/jc.2009-2509.

[pmid264449943-4] [3]
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. November 2015, 100 (11): 3975–4011. PMID 26444994. doi:10.1210/jc.2015-2236.

[pmid205666203-5] [4]
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. July 2010, 95 (7 Suppl 1): s1–s66. PMID 20566620. doi:10.1210/jc.2009-2509.

[pmid16112947-6] [5]
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2018-08-17]. PMID 16112947. doi:10.1080/13697130500148875. （原始內容存檔 (PDF)於2019-03-27）.

[Maturitas-7] [6]
Shuster, Lynne T.; Rhodes, Deborah J.; Gostout, Bobbie S.; Grossardt, Brandon R.; Rocca, Walter A. Premature menopause or early menopause: Long-term health consequences. Maturitas. 2010, 65 (2): 161–166. ISSN 0378-5122. PMC 2815011 . PMID 19733988. doi:10.1016/j.maturitas.2009.08.003.

[eden-8] [7]
Eden, K.J., & Wylie, K.R. (2009). Quality of sexual life and menopause. Women’s Health, 5 (4), 385-396. doi:10.2217/whe.09.24

[ziaei-9] [8]
Ziaei, S., Moghasemi, M., & Faghihzadeh, S. (2010). Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climateric, 13, 147-156. doi:10.1016/j.maturitas.2006.04.014

[註 1]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]